Recombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical)

重组抗HER2人源化单克隆抗体-DM1（齐鲁制药）

Report date: 2024/02/05 13:59:16

Base Information

Drug NameRecombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsTubulinReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

Originator CompaniesQilu Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A